{
  "disease_name": "Myxofibrosarcoma",
  "synonyms": [
    "MFS",
    "Malignant fibrous histiocytoma, myxoid variant",
    "Epithelioid myxofibrosarcoma"
  ],
  "summary": "Myxofibrosarcoma (MFS) is a rare but common soft tissue sarcoma, often developing in elderly individuals. It is characterized by high recurrence rates, a tendency to progress to higher grades, and potential for metastasis. The epithelioid variant is particularly aggressive.",
  "causes": [
    "Complex chromosome and/or gene abnormalities",
    "Ring chromosomes",
    "Double minutes",
    "Chromosomes with deletions",
    "Chromosome translocations"
  ],
  "risk_factors": [
    "Older age (fifth to seventh decades of life)",
    "Male sex"
  ],
  "symptoms": [
    "Painless, slowly enlarging masses in muscle, skin, or non-cutaneous areas",
    "Tumor located in extremity (usually lower extremity)",
    "Tumor located in trunk",
    "Tumor located in head and neck areas",
    "Tumor located in breast",
    "Tumor located in heart",
    "Tumor located in paratesticular region",
    "Tumor located in eye",
    "Tumor located in bone",
    "Tumor located in liver",
    "Tumor presenting in multiple sites concurrently",
    "Tumor presenting in abdominal cavity",
    "Tumor presenting in retroperitoneum",
    "Tumor presenting in pelvis"
  ],
  "diagnosis": [
    "Histopathology of tumors",
    "Presence of pseudo-lipoblasts in a myxoid sarcoma-like background",
    "Magnetic resonance imaging (MRI)",
    "T2-weighted MRI 'tail sign'"
  ],
  "treatments": [
    "Radical surgical resection",
    "Adjuvant radiotherapy",
    "Limb amputation (for unresectable limb tumors)",
    "Chemotherapy (anthracycline, Ifosfamide, gemcitabine, paclitaxel, adriamycin, dacarbazine)",
    "Angiogenesis inhibitors",
    "Immunotherapeutics (Bevacizumab, Nivolumab)"
  ],
  "related_genes": [
    "NF1",
    "CDKN2A/CDKN2B",
    "CDK6",
    "CCND1",
    "MDM2"
  ],
  "subtypes": [
    "Epithelioid myxofibrosarcoma"
  ]
}